annb0t
Top 20
By Brian Lantier, CFA
OTC:BRCHF
READ THE FULL BRCHF RESEARCH REPORT
The path to commercialization of BrainChipâs (OTC:BRCHF) Akida IP remains bumpy as second half 2022 results missed our expectations by a wide margin. Realizing recurring license revenue will be a key milestone toward building investor confidence. The company has announced a number of partnerships and agreements in early 2023 which should be net positives in the long run.
We are adjusting our model to reflect the weak se...
>>> Read more: BRCHF: Reducing revenue estimates, prospects for AI solutions remain high
OTC:BRCHF
READ THE FULL BRCHF RESEARCH REPORT
The path to commercialization of BrainChipâs (OTC:BRCHF) Akida IP remains bumpy as second half 2022 results missed our expectations by a wide margin. Realizing recurring license revenue will be a key milestone toward building investor confidence. The company has announced a number of partnerships and agreements in early 2023 which should be net positives in the long run.
We are adjusting our model to reflect the weak se...
>>> Read more: BRCHF: Reducing revenue estimates, prospects for AI solutions remain high
